Clinical trial
Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults
NCT00150774 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00150774 |
|---|---|
| Title | Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults |
| Official title | A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Treatment in Adolescents (≥ 12 Years) and Adults (≤ 65 Years) Suffering From Idiopathic Generalized… |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Convulsive Epilepsy |
| Intervention type | Drug |
| Interventions | Levetiracetam |
| Enrollment | 116 |
| Start date | Nov 1, 2001 |
| Primary completion | Dec 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Sep 8, 2005 |
| Last update posted | Sep 17, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: